Navigation Links
Most Newer Antipsychotics No Better Than Older Ones, Just Different
Date:12/5/2008

People need to find the one that works best for them, experts say

FRIDAY, Dec. 5 (HealthDay News) -- Antipsychotic drugs have traditionally been classified as "first" or "second" generation, but these classifications aren't valid and the drugs should be prescribed on a patient-by-patient basis, new research suggests.

Older drugs (first-generation) are cheaper than the newer "atypical" antipsychotic (second-generation) medications and have different side effects. But, the added cost of second-generation antipsychotics -- with an estimated $7.5 billion in U.S. sales in 2003 -- has led to debate about their benefits compared with first-generation drugs.

"In recent years there has been a number of new antipsychotic, and there had been controversy over which is the best," said study author Dr. John Davis, a research professor of psychiatry at the University of Illinois at Chicago.

"What we find is that different ones are better or worse in different ways," Davis said. "Therefore, the newer drugs can't be thought of as the same class. They each have their distinctive profile, with major differences between them."

The findings were published in the Dec. 5 online edition of The Lancet.

For the study, Davis and his colleagues reviewed 150 studies that included more than 21,000 patients. The researchers looked at overall effectiveness, side effects, depressive symptoms, relapse rates, quality of life, and weight gain, among other measures.

The analysis found four second-generation drugs, amisulpride (Solian), clozapine (Clozaril), olanzapine (Zyprexa) and risperidone (Risperdal) were more effective than first-generation drugs, with "small to medium effect sizes."

But, other second generation drugs, such as aripiprazole (Abilify), quetiapine (Seroquel), sertindole (Serdolect), ziprasidone (Geodon) and zotepine (Nipolept), were no more effective than first-generation drugs, the researchers reported.

And, only aripiprazole and ziprasidone among the second-generation drugs did not induce more weight gain than the first-generation drug haloperidol (Haldol), the study found.

Comparing first- and second-generation drugs, Davis's team also found that second-generation drugs produced fewer "extra-pyramidal" side effects such as unintentional muscle contractions, Parkinson-like symptoms and restlessness than Haldol.

However, only a few of these second-generation drugs reduced these side effects compared with low-dose Haldol, the researchers noted.

In addition to Haldol, other first generation antipsychotics include chlorpromazine (Thorazine), fluphenazine (Prolixin), mesoridazine (Serentil), perphenazine (Trilafon), and trifluoperazine (Stelazine), according to the U.S. National Institute of Mental Health.

Davis thinks that classifying these drugs as first- or second-generation should be abandoned. "For patients, there is a choice only some drugs are efficacious, only some drugs cause obesity, and only some cause tremor. The doctor should choose based on whether he wants to go for efficacy, primarily, or wants to avoid side effects and the patient's history," he said. "It's a value judgment about which one should be used."

Dr. Peter Tyrer, who's with the Department of Psychological Medicine at Imperial College London in England, and co-wrote an accompanying editorial in the journal, thinks these drugs should be evaluated on their own merit and not as part of a group of newer or older drugs.

"We should dump the labels of first- and second-generation in our descriptions of these drugs," he said. "They have been used primarily as a marketing ploy to convey the impression of a steady improvement in the benefit-risk ratio of these agents, an impression that has been exposed as completely inaccurate."

Dr. Thomas R. Insel, director of the U.S. National Institute of Mental Health, believes efforts are needed to find ways to tell which patients will respond to which of the many drugs available.

"Neither class of drugs is homogenous," Insel said. "There is not a huge difference between the classes when you look at efficacy. Where the differences emerge is largely with side effects."

"It would be wonderful," he added, "if we could know how to predict which patient is going to respond to which medication, but we don't know that yet. But we do know that just because somebody doesn't respond to the first one doesn't mean they are not going to respond to the next one."

Finding "biomarkers" that would predict which drug will work for a given patient is going to be the focus of new research, Insel said. "We really need to get serious about personalized medicine for psychiatric illnesses," he said.

More information

To learn more about antipsychotic drugs, visit the U.S. National Institute of Mental Health.



SOURCES: John Davis, M.D., research professor, psychiatry, University of Illinois at Chicago; Peter Tyrer, M.D., Department of Psychological Medicine, Imperial College London, England; Thomas R. Insel, M.D., director, U.S. National Institute of Mental Health, Bethesda, Md.; Dec. 5, 2008, The Lancet, online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer antipsychotics no better than older drug in treating child and adolescent schizophrenia
2. First generation antipsychotic drugs as effective as newer ones in some children
3. Newer Blood Pressure Drug Better for Some Heart Patients, Diabetics
4. Newer Blood Pressure Drug No Better Than Placebo in Preventing Stroke
5. Newer Prostate Cancer Treatment Similar to Traditional Surgery
6. Newer Rheumatoid Arthritis Drugs Lower Production of B Cells
7. Newer Sedative Might Help Patients on Ventilators
8. Newer Anticlotting Drug Safe, Effective for Heart Surgeries
9. Newer radiation treatment easier for some throat cancer patients
10. Newer Antibiotic Speeds TB Healing
11. Newer antidepressants led to less, not more, teen suicides
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Most Newer Antipsychotics No Better Than Older Ones, Just Different
(Date:3/1/2017)... ... March 01, 2017 , ... RJ Young, the third ... of Harris Delchamps to Director of Integrated Solution Sales. Harris has been with RJ ... Print Services. , Harris will lead sales for the IT Services and Software divisions. ...
(Date:3/1/2017)... ... March 01, 2017 , ... Eating Recovery Center (ERC), a ... Whitely as a National Binge Eating Recovery Advocate. An inspiring author and motivational speaker, ... in their fields who speak at and attend various conferences and events throughout the ...
(Date:3/1/2017)... ... ... Financial Recovery Group, Inc. (FRG), is proud to announce it will participate ... company also is offering a special discount for those who attend the event as ... the brightest minds in the healthcare industry to share information on risk adjustment, quality ...
(Date:3/1/2017)... ... , ... The Industrial Designers Society of America (IDSA) is marking National ... of industrial design (ID) and relaunching "What Is ID?" —one of the most ... parents; and the greater public. , Share details and photos of National ID Day ...
(Date:3/1/2017)... N.C. (PRWEB) , ... March 01, 2017 , ... ... to bring PurThread’s permanently embedded anti-odor solution to cotton knit and woven fabrics. ... performance attributes while maintaining the luxurious look and feel of cotton. Cotton ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... 1, 2017  The Welch Foundation, one of the ... today announced that Drs. Neal M. Alto ... recipients of the Norman Hackerman Award in ... stars, having contributed significant scientific discoveries at early stages ... the 15 years of the Hackerman Award that two ...
(Date:3/1/2017)... , March 1, 2017  The Board of Directors ... Alan Turfe as the new CEO and Chairman ... retirement of long-time Chairman and CEO William R. ... a nationwide search, and brings a wealth of experience ... industries. "In a pool of incredibly ...
(Date:2/28/2017)... , Feb. 28, 2017 Prefilled Syringes ... report: https://www.reportbuyer.com/product/4402629/ This report provides ... market on the global and regional levels. It ... from 2016 to 2024 in terms of revenue ... also includes macroeconomic indicators along with an outlook ...
Breaking Medicine Technology: